| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $144,595 | 2 | 50 |
Sells | $394,957 | 2 | 50 |
| Lee Tien-Li | Chief Executive Officer | 1 | $101,395 | 0 | $0 | $101,395 |
| Sun Nelson | Chief Financial Officer | 1 | $43,200 | 2 | $394,957 | $-351,757 |
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical …
Over the last 12 months, insiders at Aardvark Therapeutics, Inc. Common Stock have bought $144,595 and sold $394,957 worth of Aardvark Therapeutics, Inc. Common Stock stock.
On average, over the past 5 years, insiders at Aardvark Therapeutics, Inc. Common Stock have bought $225,156 and sold $394,957 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Lee Tien-Li (Chief Executive Officer) — $101,395. Sun Nelson (Chief Financial Officer) — $43,200.
The last purchase of 7,000 shares for transaction amount of $101,395 was made by Lee Tien-Li (Chief Executive Officer) on 2025‑12‑11.
| 2026-09-11 | Sale | Sun Nelson | See Remarks | 62,000 0.2861% | $5.18 | $321,179 | -7.21% | |
| 2026-09-10 | Sale | Sun Nelson | See Remarks | 14,754 0.0673% | $5.00 | $73,779 | -2.99% | |
| 2025-12-11 | Lee Tien-Li | Chief Executive Officer | 7,000 0.0348% | $14.48 | $101,395 | -64.51% | ||
| 2025-12-11 | Sun Nelson | Chief Financial Officer | 3,000 0.0148% | $14.40 | $43,200 | -64.51% | ||
| 2025-09-15 | Lee Tien-Li | Chief Executive Officer | 10,000 0.0332% | $9.66 | $96,624 | -31.56% | ||
| 2025-09-12 | Lee Tien-Li | Chief Executive Officer | 5,000 0.0146% | $8.50 | $42,516 | -20.26% | ||
| 2025-09-11 | Lee Tien-Li | Chief Executive Officer | 6,000 0.0161% | $7.82 | $46,926 | -11.68% | ||
| 2025-09-10 | Lee Tien-Li | Chief Executive Officer | 9,000 0.0245% | $7.91 | $71,213 | -11.50% | ||
| 2025-09-09 | Sun Nelson | Chief Financial Officer | 6,000 0.0166% | $8.07 | $48,440 | -9.10% | ||
| 2007-08-17 | Creamer James W III | CFO & Treasurer | 500 0.0003% | $1.90 | $950 | |||
| 2006-12-06 | Zimlich Joseph C | director | 56,550 0.0252% | $1.30 | $73,515 | |||
| 2006-05-12 | Creamer James W III | Chief Financial Officer | 300 0.0003% | $3.05 | $915 |
| Lee Tien-Li | Chief Executive Officer | 1551613 7.0899% | $1.91M | 5 | 0 | <0.0001% |
| Sun Nelson | See Remarks | 35475 0.1621% | $43,634.25 | 2 | 2 | <0.0001% |
| Zimlich Joseph C | director | 56550 0.2584% | $69,556.50 | 1 | 0 | |
| Creamer James W III | CFO & Treasurer | 50800 0.2321% | $62,484.00 | 2 | 0 |
$156,891,025 | 80 | -24.91% | $36.3M | |
$6,204,522 | 45 | 1.91% | $36.5M | |
$121,435,814 | 28 | 12.32% | $33.53M | |
$931,435 | 28 | 16.31% | $24.8M | |
$226,127 | 22 | -27.62% | $21.96M |
| Increased Positions | 49 | +132.43% | 2M | +23.22% |
| Decreased Positions | 15 | -40.54% | 917,879 | -9.7% |
| New Positions | 22 | New | 1M | New |
| Sold Out Positions | 6 | Sold Out | 512,491 | Sold Out |
| Total Postitions | 71 | +91.89% | 11M | +13.52% |